Abstract:Graphical and Lay Summary Sustainable asymmetric synthesis of a key diltiazem intermediate at industrially relevant substrate loading and space‐time yield was achieved, enabled by recombinant Escherichia coli whole cells co‐expressing an engineered ketoreductase and glucose dehydrogenase. As a key synthetic intermediate of the cardiovascular drug diltiazem, methyl (2R,3S)‐3‐(4‐methoxyphenyl) glycidate ((2R,3S)‐MPGM) (1) is accessible via the ring closure of chlorohydrin (3S)‐methyl 2‐chloro‐3‐hydroxy‐3‐(4‐methoxyphenyl)propanoate ((3S)‐2). We report the efficient reduction of methyl 2‐chloro‐3‐(4‐methoxyphenyl)‐3‐oxo‐propanoate (3) to (3S)‐2 using an engineered enzyme SSCRM2 possessing 4.5‐fold improved specific activity, which was obtained through the structure‐guided site‐saturation mutagenesis of the ketoreductase SSCR by reliving steric hindrance and undesired interactions. With the combined use of the co‐expression fine‐tuning strategy, a recombinant E. coli (pET28a‐RBS‐SSCRM2/pACYCDuet‐GDH), co‐expressing SSCRM2 and glucose dehydrogenase, was constructed and optimized for protein expression. After optimizing the reaction conditions, whole‐cell‐catalyzed complete reduction of industrially relevant 300 g/L of 3 was realized, affording (3S)‐2 with 99% ee and a space‐time yield of 519.1 g∙L−1∙d−1, representing the highest record for the biocatalytic synthesis of (3S)‐2 reported to date. The E‐factor of this biocatalytic synthesis was 24.5 (including water). Chiral alcohol (3S)‐2 generated in this atom‐economic synthesis was transformed to (2R,3S)‐MPGM in 95% yield with 99% ee. This article is protected by copyright. All rights reserved

Electrochemical Synthesis of a Sitagliptin Precursor

Enantioselective Synthesis of ( R )-Sitagliptin via Phase-Transfer Catalytic aza-Michael Addition

A Novel Asymmetric Synthesis of Cis-(3r, 4R)-N-(tert-butoxycarbonyl)-4-methyl-3-(methylamino) Piperidine

Organocatalytic asymmetric reduction of N-unsubstituted β-enamino ester with HSiCl3

Organocatalytic asymmetric reduction of <i>N</i>-unsubstituted -enamino ester with HSiCl<sub>3</sub>

Sustainable Asymmetric Synthesis of Diltiazem Precursor Enabled by Recombinant Escherichia coli Whole Cells Co‐Expressing an Engineered Ketoreductase and Glucose Dehydrogenase

SINGLE STEP SYNTHESIS OF Β– AND Γ– ARYL-SUBSTITUTED ß- AND Γ-AMINO ACID DERIVATIVES BY ELECTROCHEMISTRY

Electrochemical Oxidative Dearomatization Strategy for Accessing Spiro[4.5]dienones and Derivatives

Combining Rh-Catalyzed Diazocoupling and Enzymatic Reduction to Efficiently Synthesize Enantioenriched 2-Substituted Succinate Derivatives

Biocatalytic Synthesis of Ruxolitinib Intermediate via Engineered Imine Reductase

Chemo-enzymatic Asymmetric Synthesis of S-citalopram by Lipase-Catalyzed Cyclic Resolution and Stereoinversion of Quaternary Stereogenic Center.

FeCl3-Catalyzed Cross-Coupling for Improving the Synthesis of Upadacitinib

An Efficient Method for Synthesis of Bexagliflozin and Its Carbon-13 Labeled Analogue

Synthesis of Etrasimod (APD334): Al 2 O 3 -Promoted Decarboxylative Rearrangements of Cyclopentenones with Stereochemical Inversion

Substrate Directed Highly Diastereoselective Synthesis of Eliglustat: A Drug for Gaucher Disease

Synthesis of 6-Hydroxy-8-chlorooctanoate Ethyl Ester by Chemoenzymatic Method

Synthetic Studies Ond-Biotin, Part 8:[1] an Efficient Chemoenzymatic Approach to the Asymmetric Total Synthesis Ofd-Biotinvia a Polymer-Supported PLE-Mediated Desymmetrization Ofmeso-Symmetic Dicarboxylic Esters

An Enantioselective Synthesis of an 11-Β-hsd-1 Inhibitor Via an Asymmetric Methallylation Catalyzed by (S)-3,3'-F2-BINOL.

Creation of a robust and R-selective ω-amine transaminase for the asymmetric synthesis of sitagliptin intermediate on a kilogram scale

Total Synthesis of (+)-SCH 351448: Efficiency Via Chemoselectivity and Redox-Economy Powered by Metal Catalysis.

One‐Pot Catalytic Synthesis of Optically Active Drug (S)‐Clopidogrel